A Dallas biotech halts TIL therapy trials — shares crater nearly 30%
A Texas biotech attempting to create new cell therapies has hit pause on enrollment in clinical trials because of manufacturing issues, and the company’s shares sank about 30% after the opening bell.
Instil Bio said it has informed the FDA and regulators in Canada and the UK of its decision to stop letting new patients into the study as it looks into manufacturing issues for ITIL-168, the company’s lead tumor infiltrating lymphocyte (TIL) therapy, which is in mid- and early-stage studies for advanced melanoma and various solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.